For patients at high risk for fracture due to osteoporosis
FORTEO (teriparatide injection) can help reduce your risk of having another fracture*
FORTEO is a prescription medicine used to treat postmenopausal women who have osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis. FORTEO is used to increase the bone mass in men with primary or hypogonadal osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO is used to treat both men and women with osteoporosis due to use of glucocorticoid medicines, such as prednisone, for several months, who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments.
*Only proven in postmenopausal women with osteoporosis. All women took calcium and vitamin D daily.
Here is some important safety information you should know about FORTEO:
Possible bone cancer. During drug testing, the medicine in FORTEO caused some rats to develop a bone cancer called osteosarcoma. Studies in people have not shown that FORTEO increases your chance of getting osteosarcoma. There is little information about the chance of getting osteosarcoma in patients using FORTEO beyond 2 years.
Terms and Conditions
Subject to Lilly USA, LLC’s (Lilly’s) right to terminate, rescind, revoke or amend the Forteo Savings Card Program ( “Card”) eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, the Card expires and savings end on 12/31/2024. Card savings are not available to patients without commercial drug insurance or who are enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program.
MONTHLY AND ANNUAL MAXIMUM SAVINGS:
For patients with commercial drug insurance coverage for Forteo: You must have commercial drug insurance that covers Forteo and a prescription consistent with FDA-approved product labeling to pay as little as $4 for a 1-month prescription fill of Forteo. Month is defined as 28-days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and separate maximum annual savings of up to $9,450 per calendar year. Card may be used for a maximum of up to 13 prescription fills per calendar year. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2024.
ADDITIONAL TERMS AND CONDITIONS
You are responsible for any applicable taxes, fees and any amount that exceeds the monthly or annual maximum benefits. Savings card activation is required. This Card may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Subject to additional terms and conditions. Eligibility criteria and terms and conditions for the Forteo Savings Card Program may change from time to time at Lilly’s sole discretion and for any reason; the most current version can be found at https://www.Forteo.com/savings-and-support Card benefits void where prohibited by law.
Start managing your osteoporosis with FORTEO
Consult your healthcare provider to determine if FORTEO is right for you.
of clinical experience‡
PRESCRIBED TO OVER
2 MILLION PEOPLE§
‡FDA approval in 2002
§Cumulative worldwide exposure through 31 August 2017 across all approved indications.
FORTEO Connect™ is available for support
Joining FORTEO Connect™ provides access to a team of professionals committed to helping you get off to a good start. Support includes:
- FORTEO information and injection training
- Insurance investigation